For the last few decades stents have played a central role in the treatment of artherosclerosis. Although bare-metal stents (BMS) have significantly reduced levels of restenosis rates by 20 or 30% [1], restenosis rates remain high at around 25% [1]. The introduction of drug-eluting stents have reduced restenosis rates even further [2], but are associated with high risk of late thrombosis [3].

This content is only available via PDF.
You do not currently have access to this content.